Compare NBY & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | NBY | CTNM |
|---|---|---|
| Founded | 2000 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 398.2M | 416.1M |
| IPO Year | 2007 | 2024 |
| Metric | NBY | CTNM |
|---|---|---|
| Price | $4.67 | $12.64 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 2.3M | 251.3K |
| Earning Date | 11-07-2025 | 10-30-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.47 | N/A |
| Revenue | ★ $10,302,000.00 | N/A |
| Revenue This Year | $23.91 | N/A |
| Revenue Next Year | $32.05 | N/A |
| P/E Ratio | $177.57 | ★ N/A |
| Revenue Growth | ★ 390.34 | N/A |
| 52 Week Low | $0.46 | $3.35 |
| 52 Week High | $6.47 | $15.25 |
| Indicator | NBY | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 71.81 | 61.13 |
| Support Level | $4.37 | $11.27 |
| Resistance Level | $6.47 | $12.00 |
| Average True Range (ATR) | 0.89 | 0.70 |
| MACD | 0.28 | 0.07 |
| Stochastic Oscillator | 67.28 | 69.75 |
NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically-proven eyecare, wound care, and skin care products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material, including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.